Canopy Growth Corporation
NASDAQ:CGCDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $212.31M
- Beta
- 0.78
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 3.44M
Average 9.97M
CGC Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Canopy Growth CorporationNASDAQ: CGC
Depreciation & Amortization · Q4 FY2025 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q4 FY2025 depreciation & amortization of CA$8.65M fell 24.5% year over year, behind the -7.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 29.2% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Depreciation & amortization amounted to 10.5% of revenue in FY2025, down 5.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -24.5% toward the trailing-twelve-month pace of -7.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
CAD · from the income statement
- Latest · FY2025
- 50.86M CAD
- Year-over-year change
- +18.0%
- 4-year CAGR
- -17.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2026-03-31 | 50.86M | +18.0% |
| FY2024 | 2025-03-31 | 43.12M | -18.9% |
| FY2023 | 2024-03-31 | 53.18M | -33.6% |
| FY2022 | 2023-03-31 | 80.03M | -27.9% |
| FY2021 | 2022-03-31 | 110.94M | — |
Depreciation & Amortization vs competitors
How CGC compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.7% is the 6th highest of 9, against a peer median of -5.2%.
- Depreciation & amortization amounts to 12.7% of revenue for CGC, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $50.86M USD | -3.7% | -14.3% | 21.3% | |
| LTM Mar 2026 | CA$39.79M CAD | -7.7% | -14.0% | 12.7% | |
| LTM Mar 2026 | CA$13.44M CAD | -40.4% | -35.3% | 4.3% | |
| LTM Mar 2026 | $10.43M USD | -42.2% | -13.8% | 33645.2% | |
| LTM Mar 2026 | $9.77M USD | — | -23.7% | 7.2% | |
| LTM Mar 2026 | $6.34M USD | -2.8% | +26.1% | 15.2% | |
| LTM Mar 2026 | $1.85M USD | -6.7% | +9.9% | 0.5% | |
| LTM Mar 2026 | $1.5M USD | -16.9% | +11.8% | — | |
| LTM Mar 2026 | $528K USD | +7.3% | -17.1% | 6.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K USD | +39.8% | +18.2% | 2.3% |
| Peer median (excluding CGC) | — | -5.2% | -13.8% | 6.8% | |
Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 | FY2025 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 475.7M | 333.25M | 297.15M | 269M | 483.67M |
| Cost of Revenue | 663.11M | 396.78M | 216.26M | 189.48M | 386.51M |
| Gross Profit | (187.41M) | (63.53M) | 80.88M | 79.51M | 97.16M |
| Gross Margin | -39.4% | -19.1% | 27.2% | 29.6% | 20.1% |
| Research & Development | 32.26M | 21.72M | 4.61M | 1.91M | 0 |
| Selling, General & Admin | 361.1M | 297.98M | 180.59M | 121.71M | 223.11M |
| Operating Expenses | 831.39M | 2.57B | 309.6M | 196.65M | 322.6M |
| Depreciation & Amortization | 110.94M | 80.03M | 53.18M | 43.12M | 50.86M |
| EBITDA | (52.98M) | (2.88B) | (312.83M) | (479.31M) | 50.86M |
| EBITDA Margin | -11.1% | -864.2% | -105.3% | -178.2% | 10.5% |
| Operating Income | (1.02B) | (2.63B) | (228.71M) | (117.14M) | (161.66M) |
| Operating Margin | -214.2% | -789.3% | -77.0% | -43.5% | -33.4% |
| Interest Income | 6.6M | 24.28M | 16.24M | 8.82M | 10M |
| Interest Expense | 103.94M | 126.16M | 105.35M | 74.57M | 38.19M |
| Other Income / Expenses | 750.94M | (455.64M) | (242.64M) | (479.85M) | (101.23M) |
| Income Before Tax | (267.86M) | (3.09B) | (471.36M) | (597M) | (262.89M) |
| Pre-Tax Margin | -56.3% | -926.1% | -158.6% | -221.9% | -54.4% |
| Income Tax Expense | (8.95M) | (5.73M) | 12.33M | 7.14M | 23K |
| Net Income | (310.04M) | (3.28B) | (657.27M) | (598.12M) | (366.64M) |
| Net Margin | -65.2% | -983.7% | -221.2% | -222.4% | -75.8% |
| EPS (Basic) | (7.70) | (70.70) | (6.47) | (5.53) | (0.88) |
| EPS (Diluted) | (7.70) | (70.70) | (8.79) | (5.53) | (0.88) |
| Weighted Avg Shares | 39.13M | 46.37M | 101.63M | 107.55M | 2.98B |
| Weighted Avg Shares (Diluted) | 39.13M | 46.37M | 74.79M | 107.55M | 2.98B |
Canopy Growth Corporation
NASDAQ:CGC
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.